A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)

Authors
Category Systematic review
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 3f6e2e9514fa0bfff1bfe00c7bc4bd488f1b1901
First added on: Feb 15, 2025